Sunitinib in pancreatic neuroendocrine tumors

Targeted Oncology

Volumn 7, Issue 2, 2012, Pages 117-125

  Raymond, Eric ^a   Hammel, Pascal ^b   Dreyer, Chantal ^a   Maatescu, Christian ^a   Hentic, Olivia ^b   Ruszniewski, Philippe ^b   Faivre, Sandrine ^a  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Angiogenesis; Carcinoids; Combinations; Endocrine tumors; MTOR inhibitor; Pancreatic neuroendocrine tumor; PDGFR; PNET; Somatostatin analogues; VEGFR

Indexed keywords

ANGIOSTATIN; CD135 ANTIGEN; DOXORUBICIN; ENDOSTATIN; EVEROLIMUS; FLUOROURACIL; GELATINASE A; GELATINASE B; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTINUOUS INFUSION; DIARRHEA; ENZYME INHIBITION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; NONHUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES;

EID: 84865730001     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0220-2     Document Type: Review

References (41)

1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727-1733
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063-3072
3. Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS (2009) A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 11:422-428
4. Knigge U, Hansen CP, Stadil F (2008) Interventional treatment of neuroendocrine liver metastases. Surgeon 6:232-239
5. Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Somatostatin analogues in the treatment of gastroenteropancreatic neuroendo-crine (carcinoid) tumours. Aliment Pharmacol Ther 31:169-188
6. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656-4663
7. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189-1194 (Pubitemid 11207582)
8. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523
9. Heng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944-948 (Pubitemid 29439847)
10. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ et al (2004) Lack of efficacy of streptozocin and doxo-rubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27:485-488 (Pubitemid 39371944)
11. Klöppel G, Anlauf M (2005) Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 19:507-517 (Pubitemid 41447715)
12. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193-202 (Pubitemid 41039165)
13. Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469-1473 (Pubitemid 36418403)
14. Yao VJ, Sennino B, Davis RB, Christensen J, Hu-Lowe D, Roberts G et al (2006) Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models. Eur J Cancer 4(12):27-28
15. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, del la Peruta M et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28:245-255
16. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F (2008) Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15:257-266 (Pubitemid 351449744)
17. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6(9):507-18
18. Rodallec M, Vilgrain V, Couvelard A, Rufat P, O'Toole D, Barrau V et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77-85
19. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94-101 (Pubitemid 40188441)
20. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A (1997) A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 100:404-410 (Pubitemid 27349088)
21. Moore PS, Missiaglia E, Antonello D, Zamò A, Zamboni G, Corleto V et al (2001) Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 32:177-181
22. Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Klöppel G et al (2009) VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer 16:1219-1227
23. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F et al (2008) Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIHIs associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res 14:6634-6639
24. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203
25. Hanahan D (1985) Heritable formation of pancreatic β-cells: tumors in transgenic mice harboring recombinant insulin/simian virus 40 oncogenes. Nature 215:115-122 (Pubitemid 15064530)
26. Lopez T, Hanahan D (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1:339-353 (Pubitemid 41039136)
27. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744
28. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:393-403 (Pubitemid 37491100)
29. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812 (Pubitemid 29291347)
30. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J et al (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007 (Pubitemid 26079871)
31. Chiu CW, Nozawa H, Hanahan D (2010) Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 28:4425-4433
32. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
33. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523
34. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309 (Pubitemid 41443415)
35. Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M et al (2011) Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol 54:1073-1078
36. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745 (Pubitemid 47338181)
37. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295 (Pubitemid 36554699)
38. Tuveson D, Hanahan D (2011) Translational medicine: cancer lessons from mice to humans. Nature 471:316-317
39. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
40. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J et al (2008) Activity of sunitinib in patients with advanced neuroendo-crine tumors. J Clin Oncol 26:3403-3410
41. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102:1106-1112